A top human resources officer at Eli Lilly and Co.’s factory in New Jersey claims the drugmaker fired her in retaliation for investigating employee complaints about drug manufacturing problems and for refusing to drop the matter.
Lilly inks $275M deal to supply more COVID-19 antibody
Indianapolis-based Eli Lilly and Co. on Wednesday announced an agreement with the U.S. government to supply an additional 150,000 doses of its COVID-fighting antibody bebtelovimab.Read More
Lilly faces lawsuit over alleged excessive retirement-plan fees
The drugmaker is one of hundreds of U.S. companies being sued in the recent trend in litigation: excessive fees on 401(k) retirement plans.Read More
Boone County officials tout Lilly’s $2.1B manufacturing plan as a ‘game-changer’
Lebanon Mayor Matt Gentry called Eli Lilly’s plans to build two pharmaceutical manufacturing sites “transformational” for his city.Read More
UPDATE: Lilly to anchor state’s new innovation district with $2.1B in manufacturing facilities
The Indianapolis-based drugmaker said Wednesday the project in Boone County will create up to 500 jobs in central Indiana, along with up to 1,500 temporary construction jobs.Read More
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.
David Ricks’ lunchtime speech to The Economic Club of Indiana—repeated on social media by those in attendance and reported by IBJ and local TV stations—has reverberated across the state.
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.
When it comes to competing for jobs, Indiana is far behind the curve in critical ways, Eli Lilly and Co. CEO David Ricks told a lunch crowd Wednesday at the Economic Club of Indiana.
Since early March, the Lilly Endowment has sold 1.3 million shares of Eli Lilly and Co. stock, raising $391 million, according to government filings.
The Affordable Insulin Now Act will serve as a political vehicle to rally Democrats and force Republicans who oppose it into uncomfortable votes ahead of the midterms.
For the third year in a row, an investor is proposing that the pharmaceutical company scrap the tradition of combining the role of chief executive officer and board chair.
The Indianapolis-based pharmaceutical company said the facility is part of its strategy to advance RNA-based therapeutics and builds on its acquisition of Prevail Therapeutics, a gene therapy company based in New York.
The Indianapolis-based drugmaker said the antibody is effective against the omicron variant and it has already manufactured several hundred thousand doses. The deal calls for the federal government to pay Lilly more than $720 million.
The deal calls for the federal government to pay Eli Lilly and Co. more than $720 million for the antibody, which the company said is effective against all COVID-19 variants.
Lisa Schlehuber has served as CEO of Indianapolis-based Elements Financial since 2005. She’ll retire from the role in April, the credit union announced Wednesday.
In December, the U.S. government paused distribution of Lilly’s two previous antibodies, saying they did not appear effective against the omicron variant.
Lilly said it selected Concord, North Carolina, because of the manufacturing technology experience of the local labor force; its proximity to universities with strong science, technology, engineering and math programs; and its access to major transportation infrastructure.
Indianapolis-based Eli Lilly and Co., one of three primary U.S. insulin manufacturers, said it was “deeply disappointed by the false accusations and inaccurate claims” made by the attorney general.
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the COVID-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.